INTRODUCTION
T he complement system is an essential effector of innate immunity that plays a crucial role in the defense against common pathogens and in host homeostasis. 1 Therefore, patients with complete complement deficiencies frequently present with recurrent bacterial infections or autoimmune diseases. At opposite, overactive or deregulated complement typically results in kidney diseases. S1 Atypical hemolytic uremic syndrome (HUS) and glomerulonephritis with isolated C3 deposits (C3GN) are 2 prototypes of complementmediated kidney diseases due to deregulation of the alternative complement pathway (CAP).
2,3,S2 C3GN is driven by autoantibodies that target the C3 or C5 convertases and less frequently by pathogenic variants in the genes, regulating the complement cascade. 3 Complement Factor I gene (CFI, OMIM*217030) codes for a serine protease Factor I (FI) with an important role in CAP regulation. CFI inactivates C3b by cleaving it into iC3b, C3d, and C3dg in the presence of several cofactor proteins.
S4,S5
Deficiency of FI is a very rare primary immunodeficiency, inherited as an autosomal recessive trait. It leads to an uncontrolled amplification of C3 cleavage, resulting in a severe secondary C3 deficiency. Complete FI deficiency is strongly associated with severe and recurrent pyogenic infections (Streptococcus pneumoniae, Haemophilus influenzae, Neisseria meningitidis).
4,S5
Here we report, to our knowledge, the first case of a patient with subtotal FI deficiency with homozygous CFI pathogenic variant, which resulted in end-stage renal disease requiring kidney transplantation. This patient exhibited typical pathological findings for C3GN on renal allograft 2 years after transplantation. Strikingly, this untreated recurrent glomerular disease was not associated with infectious episodes and the patient did not develop significant renal impairment after 14 years of follow-up.
CASE PRESENTATION
A 42-year-old white woman with neither family history of renal disease nor consanguinity was referred to our department for a first renal transplantation.
Renal disease manifestations started 6 years earlier with an episode of acute kidney injury and mechanical hemolytic anemia in a context of hypertensive emergency. No kidney biopsy was performed because renal function and proteinuria significantly improved (serum creatinine 1 mg/dl and proteinuria 0.5 g/d) after blood pressure control and administration of reninangiotensin system blockers. The patient was lost to follow-up. Three years later, she was admitted for endstage renal disease requiring immediate onset of chronic intermittent hemodialysis. At this time, low C3 and FI levels were found (Table 1) (Table 1) .
After 3 years of hemodialysis, the patient underwent kidney transplantation from a deceased donor. Her pretransplantation panel reactive antibody level was 0%. Immunosuppressive regimen included prednisolone, tacrolimus, and mycophenolate mofetil without induction treatment. Posttransplant course was uneventful without infectious episodes or immunological events. Two years after transplantation, proteinuria (1.2 g/d) occurred without impairment of renal function (Table 1) . At this time, no donor-specific antibodies were detected. A renal biopsy was performed, and consisted of renal cortex with 17 glomeruli including 2 obsolescent ones. On light microscopy, glomeruli exhibited moderate mesangial expansion and hypercellularity, with glomerular capillary wall remodeling and double contour formation (Figure 2a ). Immunofluorescence study showed predominant mesangial and subendothelial C3 deposits (Figure 2b ) without evidence for IgG, IgA, or IgM deposits. C4d staining was negative on glomeruli and peritubular capillaries. Persistent proteinuria led us to perform, 2 years later, a second renal biopsy disclosing similar pathological and immunofluorescence results. Electron microscopy ( Figure 3 ) showed subendothelial and paramesangial deposits, without deposits within the glomerular basement membrane. Thrombotic microangiopathy lesions with subendothelial edema in glomerular capillaries were also present.These findings were consistent with C3GN diagnosis on renal graft without arguments for dense deposits disease. Alternative pathway hemolytic assay (AP50) and soluble terminal complement complex (sC5b-9) were repeatedly measured during follow-up. We found that AP50 was low (<10%) and sC5b-9 elevated (649, 1104, and 1205 ng/ml, normal <440) in 2016, 2017, and 2019, respectively. After 14 years of follow-up with reninangiotensin system blocker treatment, renal function remains unmodified without other specific therapeutic intervention (Table 1 ). This case description has been approved by our local institutional review board: IRB 412 Mondor no. 00003835 and by the Comité de Protection des Personnes d'Ile de France IV (no. 2016/ 25NICB).
DISCUSSION
We describe here a very rare case of C3GN occurrence in a kidney transplant recipient with homozygous pathogenic variant in CFI gene, potentially implicated in this disease. This case was characterized by a severe phenotype in native kidneys leading to end-stage renal disease, contrasting with a C3GN with only moderate proteinuria on the renal allograft. To our knowledge, only one observation of total FI deficiency associated with adult-onset immune complex glomerulonephritis (focal and segmental glomerulosclerosis with IgM and IgA focal granular deposits) has been reported. 5 This patient had a concomitant CR1 deficiency, whereas CR1 levels in our case were normal. FI is a key regulator of the complement system that acts by cleaving its substrates C3b and C4b to fragments, unable to sustain complement activation. S3 In our patient, the affected isoleucine residue, which is 
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I Boudhabhay et al.: C3 Glomerulonephritis and Factor I Deficiency buried in the interior of the serine protease domain, was substituted with a larger, sulfur-containing residue methionine. This substitution is expected to cause alteration of the local protein structure due to clashes of the methionine with the surrounding residues. Although we lack in vitro exploration of this CFI variant, the molecular modeling suggests that this genetic change can explain the reduced production. The change, though, could still be accommodated by the protein, resulting in a residual secretion and functional activity. Indeed, this genetic change was found in 2 unrelated patients with atypical HUS in a heterozygous state. S6,S7 For one of them, the FI levels were reported to be in the normal range, consistent with subtotal deficiency. S6 Moreover, the plasmatic C3 levels of our patient were just below the normal range at the time of transplantation and normalized during the follow-up, indicating residual FI activity.
Several cases of near complete FI deficiency have been reported and were found to lead to a systemic consumption of C3, Factor H, and Factor B due to uninhibited activation of the CAP. 6 Because of this consumption, opsonization with C3b cannot occur and patients are much more susceptible to recurrent pyogenic infections.
S8 Strikingly, our patient did not present any severe infectious episode before and after renal transplantation. In the present case, we could hypothesize that remaining activity of the secreted mutant protein was sufficient to prevent complete C3 depletion. CAP overactivation persisted, as evident from the depressed CAP activity (AP50) and the elevated sC5b-9 concentrations in plasma at follow-up, which could contribute to the persistent aggression of the kidney (Table 1) .
There have been reports of partial FI deficiency with rare heterozygous variants in patients who suffer from atypical HUS, 7,S9 C3GN, S10 and in age-related macular degeneration. S11 More frequently, the variant impairs the synthesis of the protein, explaining the low level of FI in plasma. None of the reported patients with atypical HUS, though, had FI below 30% of the normal range (compared with approximately 20% in this case) despite the frequent association of a consumptive deficiency of C3.
7,S9
Unfortunately, no kidney biopsy was performed on native kidneys from our patient but retrospectively the medical history was consistent with end-stage renal disease caused by complement dysregulation. In cases of severe hypertension associated with hemolytic anemia, a pathophysiological interpretation remains complex, because HUS may be a form of complementmediated disease complicated by hypertensive crisis, or a direct result of hypertension-related mechanical stress on endothelium.
8,S12 In our patient, the first episode of severe hypertensive flare with mechanical hemolytic anemia in native kidneys suggesting HUS could be retrospectively associated with the subtotal FI deficiency. Moreover, ultrastructural analysis of graft biopsy specimen revealed patterns of thrombotic microangiopathy associated with C3GN. These findings suggest a transition and a close relationship between both pathological entities, which share common molecular mechanisms consisting in dysregulation of the CAP, as previously reported.
S13
Nowadays, the use of eculizumab, an anti-C5 monoclonal antibody, is systematically discussed in cases of C3GN and/or HUS recurrence on renal allograft. However, in our case, after 14 years of follow-up, renal function remained unchanged with the exclusive use of reninangiotensin system blockers, suggesting that eculizumab was not necessary in this case, despite the elevated sC5b-9 concentration. Consistent with this finding, recent studies have shown that C3GN on renal allografts may have heterogeneous long-term renal outcome. S14,S15 Similarly, C3GN seems to have a variable course on native kidneys, and eculizumab is potentially more efficient in cases of crescentic rapidly progressive C3GN, whereas the benefit seems limited in non-rapidly progressive forms. 9 Complement gene variants strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical HUS, with a higher risk in cases of Complement Factor H mutations than CFI mutations. S16 To our knowledge, until now, no CFI homozygous mutations have been described in posttransplantation recurrence of C3GN and HUS. Further studies with large cohorts using the new C3GN classification are needed to more accurately describe the impact of complement genetics and treatment of C3GN posttransplant recurrence.
This case emphasizes the complexity of genotype/ phenotype correlation of complement-mediated renal diseases (Table 2) . Understanding the mediators of renal disease progression should be the first step to define future optimal therapy.
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